secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001104659-24-102988
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics appoints Morgan Conn, Ph.D. as CFO effective Oct 14, 2024
------------------------------------------------------------------------------

- Morgan Conn, formerly CBO of Pharvaris, appointed CFO; effective October 14, 2024.
- Annual base salary of $470,000; target bonus of 40% of base; $100,000 signing bonus.
- Equity award: option to purchase 360,890 shares and RSU covering 60,148 shares.
- Option vests 25% on first anniversary, remainder monthly over 3 years; RSU vests 25% first year, quarterly thereafter.
- Severance includes 9 months salary and COBRA, extended to 12 months upon change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/0001104659-24-102988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/tm2424946d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-102988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer